Hydrogel could be potential treatment for metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 38% of the global population, with prevalence continuing to rise in parallel with the global burden of metabolic syndrome. Although several pharmacological agents are currently under clinical investigation, approv
<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 38% of the global population, with prevalence continuing to rise in parallel with the global burden of metabolic syndrome. Although several pharmacological agents are currently under clinical investigation, approv</p>